Multiple Sclerosis, Relapsing-Remitting
Conditions
Brief summary
HLA-DRB1 \* Gene and some genes involved in inflammation and immunity (IL-7R, GPC5, CTSS) have been linked to risk of MS and the response to treatment with immunomodulators. This research aims to estimate the risk that confers some variations in the sequence of these genes.
Detailed description
Genes HLA-DRB1 \* and some genes involved in inflammation and immunity have been linked to risk of MS and the response to treatment with immunomodulators. The HLA-DRB1 \* genes have been associated with risk and response to treatment in MS in multiple studies; however, other genes have been controversial. This research aims to estimate the risk for MS that confers some variations in the sequence of IL-7R, GPC5, CTSS, HLA-DRB1 genes. Furthermore, it seeks to determine whether these gene variants (polymorphisms) are associated with treatment response to immunomodulators. Subjects with MS and healthy subjects will be taken to assess the risk for MS. Besides the investigators obtain the medical history of relapse to assess response to treatment in accordance with Expanded Disability Status Scale (EDSS) and relapses.
Interventions
GENETICPolymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
Sponsors
Instituto Mexicano del Seguro Social
University of Guadalajara
Instituto Jalisciense de Cancerologia
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
for Cases: * Subjects with multiple sclerosis * 18 and over * EDSS less than 5 * Signed informed consent Inclusion Criteria for Controls: * Healthy subjects * 18 and over * Signed informed consent
Exclusion criteria
for Cases: * Mental retardation * Withdrawal of consent * No immunomodulatory treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment response evaluated by relapses per year, evaluated during two years after recruitment. | Two Years | Treatment response evaluated by relapses per year during two years after recruitment. The relapses are defined by any neurological sign or symptom that happens at least 30 days after any previous neurological deterioration episode began. |
| Treatment response evaluated by Expanded Disability Status Scale (EDSS) during two years after recruitment. | Two Years | Treatment response evaluated by Expanded Disability Status Scale (EDSS) during two years after recruitment. The EDSS scale ranges from 0 to 10; the increments are in 0.5. Scoring is based on an examination by a neurologist about the level of disability. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Multiple Sclerosis Risk Conferred by Single Nucleotide Polymorphisms (SNPs) of Interleukins, Glypican, and Human Leukocyte Antigen Genes. | One Year | The risk conferred by SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes: calculated by odds ratio when the allele frequencies of SNPs cases are compared with the allele frequencies of SNPs in healthy subjects. |
Countries
Mexico
Contacts
Primary ContactJOSE A. CRUZ RAMOS, PhD
Backup ContactEMMANUEL DE LA MORA JIMENEZ, PhD
Outcome results
None listed